These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 24012395)

  • 1. Targeting receptor tyrosine kinases in solid tumors.
    Zhang J; Hochwald SN
    Surg Oncol Clin N Am; 2013 Oct; 22(4):685-703. PubMed ID: 24012395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinases as targets in the treatment of solid tumors.
    Giamas G; Man YL; Hirner H; Bischof J; Kramer K; Khan K; Ahmed SS; Stebbing J; Knippschild U
    Cell Signal; 2010 Jul; 22(7):984-1002. PubMed ID: 20096351
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Kinase inhibitors and their resistance].
    Togashi Y; Nishio K
    Nihon Rinsho; 2015 Aug; 73(8):1323-9. PubMed ID: 26281685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Protein tyrosine kinase inhibitors in cancer therapy].
    Boutayeb S; Zakkouri FZ; Aitelhaj M; Mesmoudi M; Boutayeb A; Boutayeb W; Mrabti H; Errihani H
    Pathol Biol (Paris); 2012 Aug; 60(4):229-33. PubMed ID: 22743095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA; Wilhelm S; Carter C; Kelley SL
    Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of receptor tyrosine kinase-based signal transduction as specific target for cancer treatment.
    Roussidis AE; Karamanos NK
    In Vivo; 2002; 16(6):459-69. PubMed ID: 12494890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of tyrosine kinase inhibitors in cancer therapy.
    Arora A; Scholar EM
    J Pharmacol Exp Ther; 2005 Dec; 315(3):971-9. PubMed ID: 16002463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.
    Hojjat-Farsangi M
    J Drug Target; 2016; 24(3):192-211. PubMed ID: 26211367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small tyrosine kinase inhibitors as key molecules in the expression of metalloproteinases by solid tumors.
    Stahtea XN; Kousidou OCh; Roussidis AE; Tzanakakis GN; Karamanos NK
    Connect Tissue Res; 2008; 49(3):211-4. PubMed ID: 18661345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting RET receptor tyrosine kinase activation in cancer.
    Phay JE; Shah MH
    Clin Cancer Res; 2010 Dec; 16(24):5936-41. PubMed ID: 20930041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New targeted therapies for gastric cancer.
    Asaoka Y; Ikenoue T; Koike K
    Expert Opin Investig Drugs; 2011 May; 20(5):595-604. PubMed ID: 21406037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibitors of growth factor signalling.
    Wakeling AE
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S183-7. PubMed ID: 16113095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting EGFR in non-small-cell lung cancer: lessons, experiences, strategies.
    Stella GM; Luisetti M; Inghilleri S; Cemmi F; Scabini R; Zorzetto M; Pozzi E
    Respir Med; 2012 Feb; 106(2):173-83. PubMed ID: 22104541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors.
    Nelson MH; Dolder CR
    Ann Pharmacother; 2006 Feb; 40(2):261-9. PubMed ID: 16418322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small molecule tyrosine kinase inhibitors in the treatment of solid tumors: an update of recent developments.
    Steeghs N; Nortier JW; Gelderblom H
    Ann Surg Oncol; 2007 Feb; 14(2):942-53. PubMed ID: 17103252
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors.
    Montero JC; Seoane S; Ocaña A; Pandiella A
    Clin Cancer Res; 2011 Sep; 17(17):5546-52. PubMed ID: 21670084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel dual Src/Abl inhibitors for hematologic and solid malignancies.
    Schenone S; Brullo C; Musumeci F; Botta M
    Expert Opin Investig Drugs; 2010 Aug; 19(8):931-45. PubMed ID: 20557276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted therapy for solid tumors: current status.
    Zureikat AH; McKee MD
    Surg Oncol Clin N Am; 2008 Apr; 17(2):279-301, vii-viii. PubMed ID: 18375353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting anaplastic lymphoma kinase in lung cancer.
    Shaw AT; Solomon B
    Clin Cancer Res; 2011 Apr; 17(8):2081-6. PubMed ID: 21288922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.